Get the Stockscreener App
4.18
2.20%
0.09
After Hours:
4.15
-0.03
-0.72%
Zentalis Pharmaceuticals Inc stock is traded at $4.18, with a volume of 834.05K.
It is up +2.20% in the last 24 hours and up +55.39% over the past month.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
See More
Previous Close:
$4.09
Open:
$4.14
24h Volume:
834.05K
Relative Volume:
0.46
Market Cap:
$297.56M
Revenue:
$26.87M
Net Income/Loss:
$-137.06M
P/E Ratio:
-2.1904
EPS:
-1.9083
Net Cash Flow:
$-125.25M
1W Performance:
+5.56%
1M Performance:
+55.39%
6M Performance:
+221.54%
1Y Performance:
+234.40%
1-Day Range:
$3.902
$4.20
1-Week Range:
$3.885
$4.32
52-Week Range:
$1.13
$6.95
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
(858) 263-4333
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
4.18 | 291.15M | 26.87M | -137.06M | -125.25M | -1.9083 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Resumed | Wells Fargo | Equal Weight |
| Aug-12-24 | Upgrade | Wedbush | Underperform → Neutral |
| Jun-20-24 | Downgrade | UBS | Buy → Neutral |
| Jun-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-18-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-18-24 | Downgrade | Wedbush | Neutral → Underperform |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-08-23 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-07-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-12-22 | Initiated | Cowen | Outperform |
| Apr-06-22 | Initiated | Wells Fargo | Overweight |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-29-21 | Initiated | Oppenheimer | Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Jan-20-21 | Initiated | Wedbush | Outperform |
| Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Guggenheim | Buy |
| Apr-28-20 | Initiated | Jefferies | Buy |
| Apr-28-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
Zentalis Starts Pivotal Phase 3 ASPENOVA Ovarian Cancer Trial - TipRanks
Zentalis begins phase 3 trial of ovarian cancer drug By Investing.com - Investing.com Canada
Zentalis begins phase 3 trial of ovarian cancer drug - Investing.com
Zentalis starts global Phase 3 ovarian cancer trial against chemotherapy - Stock Titan
Zentalis doses first patient in Phase 3 ASPENOVA trial for Cyclin E1-positive PROC - TradingView
Phase 3 ovarian cancer trial starts for Zentalis (Nasdaq: ZNTL) drug azenosertib - Stock Titan
Zentalis Pharmaceuticals Announces First Patient Dosed in - GlobeNewswire
Zentalis Pharmaceuticals (ZNTL) price target increased by 19.05% to 5.83 - MSN
Zentalis Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(4) - marketscreener.com
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Zentalis hire gets 26,000 stock options at $4.09 a share - Stock Titan
[ARS] Zentalis Pharmaceuticals, Inc. SEC Filing - Stock Titan
Zentalis (ZNTL) schedules 2026 virtual meeting on directors, auditor and executive pay - Stock Titan
ZNTL Technical Analysis | Trend, Signals & Chart Patterns | ZENTALIS PHARMACEUTICALS INC (NASDAQ:ZNTL) - ChartMill
Zentalis Pharmaceuticals (ZNTL) Price Target Decreased by 14.14% to 5.42 - MSN
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer - The Manila Times
Zentalis Pharmaceuticals Announces Abstract Acceptance at - GlobeNewswire
Ovarian cancer drug combo data lands June ASCO presentation - Stock Titan
Zentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the Target - Insider Monkey
ZNTL: Zentalis Presents Promising Data on Azenosertib at AACR 20 - GuruFocus
Zentalis Surges 20% on WEE1 Inhibitor Dose Selection—But Is Aprea the Real Winner in This Space? - Barchart.com
Zentalis presents preclinical data on cancer drug azenosertib By Investing.com - Investing.com Canada
Zentalis Highlights New Azenosertib Data in Breast Cancer - TipRanks
Zentalis Pharmaceuticals Presents Promising Preclinical Data on Azenosertib in Triple-Negative Breast Cancer and Insights on Cyclin E1-Positive Ovarian Cancer at AACR 2026 - Quiver Quantitative
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026 - ChartMill
Zentalis (Nasdaq: ZNTL) unveils azenosertib TNBC and Cyclin E1 ovarian cancer data at AACR 2026 - Stock Titan
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates - ADVFN
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Brokerages - MarketBeat
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection Milestone - Yahoo Finance
Guggenheim Increases Zentalis Price Target, Sparking Investor Interest - timothysykes.com
Zentalis Stock Jumps as Guggenheim Lifts Price Target on Cancer Program Success - StocksToTrade
Zentalis Pharmaceuticals: Price Target Boost Sparks Speculative Momentum - timothysykes.com
Is Zentalis Pharmaceuticals (NASDAQ:ZNTL) In A Good Position To Deliver On Growth Plans? - Moomoo
What's Behind The Surge In Zentalis Stock? - Sahm
Jefferies raises Zentalis stock price target on ovarian cancer trial data - Investing.com Canada
This small-cap biotech stock just hit a near 22-month high – but this analyst still expects another 56% rally - MSN
What's behind the surge in Zentalis stock? - MSN
Today's Analyst Rating Update for ZNTL: Buy Rating Maintained wi - GuruFocus
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Raised to $10.00 - MarketBeat
H.C. Wainwright reiterates Zentalis stock rating on pivotal dose selection By Investing.com - Investing.com Canada
Azenosertib Shows Promising Results in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer: Zentalis Advances Registration-Intent Trials - Minichart
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer - Bitget
Zentalis Advances Azenosertib Dose in DENALI Phase 2 - TipRanks
Zentalis Selects 400mg QD 5:2 Azenosertib Dose for Pivotal Ovarian Cancer Study - National Today
Zentalis selects 400mg dose for ovarian cancer drug trial By Investing.com - Investing.com UK
Zentalis selects 400mg QD 5:2 as pivotal azenosertib dose; DENALI topline due YE2026 - TradingView
Azenosertib 400mg dose to anchor Zentalis (NASDAQ: ZNTL) late-stage ovarian cancer trials - Stock Titan
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib - GlobeNewswire
Is Zentalis Pharmaceuticals (ZNTL) Stock Gaining Momentum | Price at $2.66, Up 1.14%Expert Market Insights - Cổng thông tin điện tử tỉnh Lào Cai
ZNTL Should I Buy - Intellectia AI
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zentalis Pharmaceuticals Inc Stock (ZNTL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bruns Ingmar | Chief Medical Officer |
Feb 09 '26 |
Sale |
2.39 |
335 |
802 |
33,332 |
| Vultaggio Vincent | PAO and PFO |
Feb 06 '26 |
Sale |
2.43 |
29,951 |
72,772 |
156,779 |
| Vultaggio Vincent | PAO and PFO |
Feb 10 '26 |
Sale |
2.42 |
6,894 |
16,699 |
146,506 |
| Vultaggio Vincent | PAO and PFO |
Feb 09 '26 |
Sale |
2.39 |
3,379 |
8,086 |
153,400 |
| EASTLAND JULIA MARIE | CEO & President |
Feb 06 '26 |
Sale |
2.43 |
7,866 |
19,112 |
80,022 |
| EASTLAND JULIA MARIE | CEO & President |
Feb 09 '26 |
Sale |
2.39 |
889 |
2,127 |
79,133 |
| Vultaggio Vincent | PAO and PFO |
Feb 02 '26 |
Sale |
2.55 |
2,540 |
6,477 |
187,286 |
| Vultaggio Vincent | PAO and PFO |
Feb 03 '26 |
Sale |
2.52 |
556 |
1,398 |
186,730 |
| WALTERS GROUP | 10% Owner |
Dec 31 '25 |
Buy |
1.20 |
6,459,973 |
7,751,968 |
13,509,973 |
| Matrix Capital Management Comp | 10% Owner |
Dec 15 '25 |
Sale |
1.33 |
7,500,000 |
9,975,000 |
6,459,973 |
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):